Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-4: 58-Week Open-label Trial of Tavapadon in Parkinson's Disease
2019-002952-17Phase 3Active
- Sponsor
- Cerevel Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tavapadon in Parkinson's disease (PD), sponsored by Cerevel Therapeutics. Primary endpoint: Long-term safety and tolerability of tavapadon. Started Sep 2020; status: active.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-002952-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002952-17.